Resumen de: EP3808372A1

A Shigella flexneri O-antigen of a first serotype or subserotype for use in raising an immune response against one or more Shigella flexneri O-antigen of a different serotype or subserotype, together with associated binding moieties, pharmaceutical compositions, kits, uses or methods.

Resumen de: WO2020014543A2

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin- and/or pagP -. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd -, purI - and msbB -. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment or tumor-resident immune cells and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

Resumen de: WO2016115097A2

The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.

Resumen de: WO2016115097A2

The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.

Resumen de: CN112649606A

本发明公开了一种基于鸡白痢沙门氏菌X蛋白包被的抗体ELISA检测方法，涉及家禽细菌性疾病检测领域；本发明通过制备和纯化鸡白痢沙门氏菌的SPF鸡源高亲和力多克隆抗体，采用免疫共沉淀技术筛选鉴定电子传递链中的电子载体、兼具氧化还原酶活性的优势抗原X蛋白；构建、表达并以特定温和方法纯化外分泌的优势抗原X蛋白；建立检测鸡白痢沙门菌抗体的间接ELISA方法。本发明能有效检出鸡白痢沙门菌阳性抗体，并提高了现有检测技术的特异性、灵敏性；为企业鸡白痢沙门氏菌净化提供了有力工具。

Resumen de: CN112618706A

本发明属于兽用生物制品技术领域，具体涉及一种沙门氏菌、鸭疫里默氏杆菌、大肠埃希氏杆菌病三联疫苗。抗原为灭活的鼠伤寒沙门氏菌S01株、鸭疫里默氏杆菌R01株和大肠埃希氏杆菌E01株。本发明的疫苗所使用的三种菌株毒力强高、免疫原性好并具有较好的交叉保护性。本发明制备的疫苗的安全性良好，未出现由疫苗引起的任何局部和全身不良反应。保存期试验中经过性状、安全性试验、效力试验数据的分析，各项指标均稳定有效；效力试验结果证明，三联灭活疫苗能产生良好抗体，并能产生较好的攻毒保护力。

Resumen de: US2021102941A1

A method for manufacturing a structure for microbe detection comprises the steps of: reacting nitrilotriacetic acid (NTA) and an acid anhydride to prepare a first compound; chelation of metal ions to the first compound to prepare a second compound; binding the second compound and a microbe detector to prepare a third compound; and mixing an exfoliated transition metal-dichalcogenide (TMD) compound and the third compound to prepare a structure for microbe detection, in which the metal ions of the third compound are bound with the transition metal-dichalcogenide compound.

Resumen de: WO2021063163A1

Provided is a method for preparing feed by bacterium-enzyme synergistic fermentation, relating to the technical field of fermentation engineering. Lactobacillus plantarum JUN-DY-6, protease, and cellulase are used as leavening agents, camellia seed meal or rapeseed meal are used as substrates, the yield of products after bacterium-enzyme fermentation, i.e., an organic acid and a flavor substance, is improved, the palatability is increased, and the method can be used for preparing a feed additive. The lactobacillus plantarum can also inhibit the growth of harmful bacteria such as escherichia coli, staphylococcus aureus, and salmonella in intestinal tracts of livestock and poultry, and is beneficial for intestinal health. The method further increases the added value of the camellia seed meal or rapeseed meal, and is beneficial for the recycling of waste.

Resumen de: US2021100265A1

Methods of preventing or decreasing PEDv and/or Salmonella bacteria in animal feed, feed ingredients, and pet food are provided. The methods utilize generally safe chemical mitigants, such as medium chain fatty acids, essential oils, and sodium bisulfate. The chemical mitigants are introduced to the feed or feed ingredients at inclusion rates selected so as to prevent or decrease PEDv and/or Salmonella bacteria in the animal feed, feed ingredients, or pet rood. The methods are particularly suitable for use in post-processing treatment of animal feed, feed ingredients, or pet food that will be transported and stored for multiple days or weeks.

Resumen de: EP3799883A1

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

Resumen de: US2014154286A1

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

Resumen de: CN112587659A

本发明公开了一种沙门菌菌蜕疫苗的制备方法及应用，利用λ‑Red系统制备获得鸡白痢沙门菌pagC基因缺失突变株ΔPagC；取过夜培养的ΔPagC菌液，1:100接种到50ml液体LB培养基中，37℃、180rpm振荡培养至OD值约0.8；4℃，5000rpm离心10min后用无菌的PBS缓冲液洗涤3次，然后用终浓度为50μM的MAP溶液重悬菌体至OD值为0.3，21℃恒温静置16h，4℃、5000rpm离心10min收集菌体，进行灭菌效果检测和核酸残留检测；检测合格后调整剂；与佐剂1:1混合，充分乳化后接种动物。本发明疫苗株接种小鼠后无不良反应，可保护小鼠应对鸡白痢沙门菌CVCC1800、肠炎沙门菌ATCC19585和鼠伤寒沙门菌CVCC542的感染；该疫苗能够能与基于PagC蛋白的沙门菌抗体间接ELISA检测试剂盒联用，实现沙门菌人工免疫和自然感染的鉴别诊断，表现出良好的DIVA特性。

Resumen de: US2021093705A1

The present disclosure relates to nanoparticle compositions for use as vaccines against Salmonella. Disclosed herein is a composition comprising: a Salmonella enteritidis outer membrane protein (OMP) or Salmonella enteritidis killed whole antigenic extracted (KAg) protein; and a polyanhydride or chitosan nanoparticle. In some embodiments, the nanoparticle further comprises flagellar protein. Disclosed herein is a vaccine comprising: a composition comprising a Salmonella enteritidis OMP protein or Salmonella enteritidis killed whole antigenic extracted (KAg) protein; a polyanhydride or chitosan nanoparticle; and a pharmaceutically acceptable carrier.

Resumen de: EA202000005A1

Изобретение относится к ветеринарной биотехнологии, в частности к производству моно- и поливалентных сывороток для комплексного лечения и профилактики вирусных, бактериальных и смешанных вирусно-бактериальных заболеваний у молодняка крупного рогатого скота. Предложен способ получения гипериммунной сыворотки против инфекционных заболеваний вирусной, бактериальной и вирусно-бактериальной этиологии крупного рогатого скота, включающий иммунизацию волов-продуцентов и/или быков на откорме путём по меньшей мере трёхкратной инъекции перед забором крови в заданном количестве доз и/или антигена в заданной концентрации с последующим получением из забранной крови сыворотки крови. При этом одновременно со второй инъекцией, а также каждый раз за 48-24 ч до забора крови вводят препарат "Биферон-Б" в объёме 10,0-15,0

Resumen de: EP3798320A1

A bacterium capture microfluidic device for ultrafast and highly sensitive analysis of the presence of bacteria in a liquid sample. The analysis is based on capture and lysis of viable bacteria on antibodies functionalized and lyophilized on chip, DNA amplification and visual detection.

Resumen de: EP3797598A1

The present disclosure is directed to a protective culture comprising an effective amount of at least one strain of Hafnia alvei for preventing, inhibiting or reducing the growth of at least one foodborne pathogenic bacteria, such as from the genus Salmonella or Staphylococcus and/or the increase in concentration of the associated toxin production (e.g., produced by the at least one foodborne pathogenic bacteria) in a final food product. The present disclosure also relates to a method for reducing preventing, inhibiting or reducing the growth of at least one foodborne pathogenic bacteria in a food product by using a strain of H. alvei. Furthermore, the present disclosure is directed to the use of H. alvei for securing microbial safety of fermented food products.

Resumen de: CN112546210A

本发明公开了一种沙门菌基因突变株灭活疫苗的制备方法及应用，利用λ‑Red系统制备获得鸡白痢沙门菌pagC基因缺失突变株ΔPagC。取过夜培养的ΔPagC菌液，1:100接种到50ml液体LB培养基中，37℃、180rpm振荡培养至OD值约0.8；加入终浓度为0.4％的甲醛溶液，继续振荡培养16h，4℃、5000rpm离心10min后收集菌体，用无菌的PBS缓冲液洗涤重悬3次后获得原液。调整好剂量与佐剂1:1混合，充分乳化后接种动物。本发明通过制备沙门菌灭活疫苗，疫苗株接种小鼠后无不良反应，可保护小鼠应对鸡白痢沙门菌CVCC1800、肠炎沙门菌ATCC19585和鼠伤寒沙门菌CVCC542的感染。该疫苗能够能够与基于PagC蛋白的沙门菌抗体间接ELISA检测试剂盒联用，实现沙门菌人工免疫和自然感染的鉴别诊断，表现出良好的DIVA特性。

Resumen de: WO2021055092A1

Embodiments described herein may be useful in the detection of analytes. The systems and methods may allow for a relatively simple and rapid way for detecting analytes such as chemical and/or biological analytes and may be useful in numerous applications including sensing, food manufacturing, medical diagnostics, performance materials, dynamic lenses, water monitoring, environmental monitoring, detection of proteins, detection of DNA, among other applications. For example, the systems and methods described herein may be used for determining the presence of a contaminant such as bacteria (e.g., detecting pathogenic bacteria in food and water samples which helps to prevent widespread infection, illness, and even death). Advantageously, the systems and methods described herein may not have the drawbacks in current detection technologies including, for example, relatively high costs, long enrichment steps and analysis times, and/or the need for extensive user training. Another advantageous feature provided by the systems and methods described herein includes fabrication in a relatively large scale. In some embodiments, the systems and methods may be used in conjunction with a detector including handheld detectors incorporated with, for example, smartphones (e.g., for the on-site detection of analytes such as pathogenic bacteria).

Resumen de: US2021085772A1

The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.

Resumen de: WO2016075250A1

The present application relates to arenaviruses with rearrangements of their open reading frames ("ORF") in their genomes. In particular, described herein is a modified arenavirus genomic segment, wherein the arenavirus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented arenavirus particles comprising one L segment and two S segments or two L segments and one S segment. The arenavirus, described herein may be suitable for vaccines and/or treatment of diseases and/or for the use in immunotherapies.

Resumen de: WO2021053242A2

The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.

Resumen de: WO2021055474A1

This disclosure relates to a method of evaluating effects of probiotic supplementation on performance and Salmonella load in broilers challenged with Salmonella enterica serovar Enteritidis, said probiotic containing Bacillus subtilis, Bacillus licheniformis, and a cellulose carrier. This disclosure relates to a method of evaluating effects of probiotic supplementation on performance and Salmonella load in broilers challenged with Salmonella enterica serovar Enteritidis, said probiotic containing Bacillus subtilis, Bacillus licheniformis, and a cellulose carrier. The present invention relates to a method of administration of probiotic supplements or treating caecal Salmonella load, and Salmonella contamination in meat of chicken broilers using a probiotic containing Bacillus subtilis and Bacillus licheniformis. The probiotic supplement can optionally contain one or more additional components such as cellulose carrier.

Resumen de: WO2020030654A1

The present invention relates to polypeptides self-assembling into nanoparticles. In particular, the invention relates to a polypeptide comprising an amino acid sequence I (SEQ ID NO: 1), a nucleic acid sequence encoding said polypeptide, a nanoparticle comprising at least one polypeptide of the invention, a complex comprising said nanoparticle and one or more cargo molecules, and a method for transfecting a cell with said complex.

Resumen de: US2021080456A1

Embodiments described herein may be useful in the detection of analytes. The systems and methods may allow for a relatively simple and rapid way for detecting analytes such as chemical and/or biological analytes and may be useful in numerous applications including sensing, food manufacturing, medical diagnostics, performance materials, dynamic lenses, water monitoring, environmental monitoring, detection of proteins, detection of DNA, among other applications. For example, the systems and methods described herein may be used for determining the presence of a contaminant such as bacteria (e.g., detecting pathogenic bacteria in food and water samples which helps to prevent widespread infection, illness, and even death). Advantageously, the systems and methods described herein may not have the drawbacks in current detection technologies including, for example, relatively high costs, long enrichment steps and analysis times, and/or the need for extensive user training. Another advantageous feature provided by the systems and methods described herein includes fabrication in a relatively large scale. In some embodiments, the systems and methods may be used in conjunction with a detector including handheld detectors incorporated with, for example, smartphones (e.g., for the on-site detection of analytes such as pathogenic bacteria).

Resumen de: US2021077605A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.